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Since the emergence of Canine parvovirus (CPV-2) in the late 1970s, CPV-2 has evolved consecutively
new antigenic types, CPV-2a and 2b. Although CPV-2 did not have a feline host range, CPV-2a and 2b
appear to have gained the ability to replicate in cats. Recent investigations demonstrate the prevalence of
CPV-2a and 2b infection in a wide range of cat populations. We illustrate the pathogenic potential of CPV
in cats and assess the risk caused by CPV variants. 
uman health and animal welfare continue to be chal-
lenged by rapidly evolving pathogens. Although many
details about specific host-parasite systems have been
reported, our understanding of host range alteration and the
evolution of virulence remains rudimentary. We reviewed the
evolution of carnivore parvoviruses with particular reference
to Canine parvovirus (CPV) infection in cats. These parvovi-
ruses’ molecular and phenotypic evolutionary pattern provides
an exemplary system to study pathogen-host relationships and
the evolution of virulence, both essential factors for under-
standing newly emerging infectious diseases.
Emergence of Mink enteritis virus 
and CPV Type 2 (CPV-2)
Infection by Feline parvovirus was thought only to occur
in cats (Feline panleukopenia virus, FPLV) or raccoons until
the mid-1940s, when a similar disease with a mortality of up to
80% was observed in infected mink kits in Canada (1). The
disease caused by the mink agent, named Mink enteritis virus
(MEV), was thereafter observed throughout many regions of
the world (2). Since MEV was indistinguishable from FPLV
by conventional methods such as serum-neutralization assay,
MEV isolates have been differentiated from FPLV primarily
on the basis of the host from which they are isolated. Using a
panel of monoclonal antibodies (MAbs), we now classify
FPLV and MEV isolates into three antigenic types, FPLV and
MEV type 1 (MEV-1) group, MEV type 2 (MEV-2), and MEV
type 3 (2,3) (Figure 1). MEV-1 and MEV-2 have repeatedly
been isolated from the mink in the United States, Europe, Japan,
and China (2,3; Y. Ikeda and M. Mochizuki, unpub. data). 
In the late 1970s, another virus emerged in dogs (4,5). The
new virus, designated CPV-2 to distinguish it from an unre-
lated Canine parvovirus (Canine minute virus), spread around
the world within a few months (6,7). CPV-2 spread rapidly,
killing thousands of dogs. Polyclonal antibody and in vivo
cross-protection studies soon showed that CPV and FPLV
were closely related antigenically, while CPV-2 and FPLV
were distinguishable from each other when examined with a
panel of MAbs (Figure 1). Subsequent extensive genetic anal-
ysis of numerous CPV-2, FPLV, and MEV isolates showed that
the viruses form two distinct clusters represented by FPLV-
type viruses from cats (FPLV), raccoons, and mink (MEV),
and by CPV-type viruses from dogs and raccoon dogs. At least
11 conserved nucleotide differences (7 nonsynonymous and 4
synonymous changes) were seen between CPV-2 isolates and
FPLV-type viruses in the capsid VP2 sequence; in contrast,
CPV and FPLV isolates differ in <2% of their genomic DNA
sequences (8) (Figure 2; Table). 
Hypotheses on the Ancestor of CPV-2
Retrospective investigations to detect CPV antibodies in
sera collected from dogs or related canids showed that the first
positive titers were present in European dogs around 1975,
while the first positive sera in the USA, Japan, and Australia
were seen in early 1978. Various hypotheses on the
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Figure 1. Antigenic profile of feline parvoviruses, including Canine par-
vovirus 2c (CPV-2c) types. Subtype-specific monoclonal antibodies are
used to type the viruses in a hemagglutinin-inhibition test (HI). Mink
enteritis virus (MEV-3) shows similar patterns to MEV-2 (2). FPLV =
Feline panleukopenia virus; BFPV = blue fox parvovirus.PERSPECTIVES
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mechanism of virus evolution in this group have been devel-
oped. The most widely accepted hypothesis is the emergence
of CPV-2 from a variant of FPLV or of a closely related virus
infecting another carnivore, such as mink or foxes (9,10). 
Several intriguing observations support the latter hypothe-
sis. First, based on the sequence analyses of the capsid VP-2
and the nonstructural NS1 genes, MEV is closer to CPV-2 than
FPLV (9,11). More importantly, the virus isolated from an
Arctic fox from Finland (blue fox parvovirus, BFPV) in 1983
appeared to be an intermediate between the FPLV- and CPV-
type viruses. BFPV had three synonymous nucleotide changes
in the VP2 gene that were specific for the canine sequence (12)
(Figure 2), while the fox virus was classified antigenically as
typical MEV-2-type (13) (Figure 1). These findings indicate
that some animals in the family Canidae, such as mink or
foxes, which are susceptible to FPLV-like viruses, might play a
role as a reservoir for the ancestor of CPV. Recently, Truyen et
al. (14) reported that the intermediate parvovirus sequence
from a German red fox was CPV-2-like but had one FPLV-spe-
cific nonsynonymous substitution. This suggests that German
red foxes could harbor the direct ancestor of CPV, although it
remains possible that the intermediate red fox parvovirus
emerged from conventional CPV-2 by one point natural muta-
tion (Figure 3). 
Emergence of CPV Types 2a 
and 2b (CPV-2a and CPV-2b)
Since the emergence of CPV-2, two new antigenic types of
CPV, designated CPV-2a and CPV-2b, have arisen consecu-
tively. These new virus types have now almost completely
replaced CPV-2 viruses as the dominant infectious agents (15)
(Figure 3). At least four conserved nonsynonymous substitu-
tions have been observed between CPV-2 and CPV-2a isolates
in the VP2 gene (Table). CPV-2b isolates have another two
nonsynonymous changes from CPV-2a (Table). Although the
exact mechanisms of these evolutions are not clear, the emer-
gence of these new antigenic types of CPV can likely be
ascribed to the adaptation of CPV-2-type viruses in dogs. Of
interest, each new antigenic type has lost at least one neutraliz-
ing epitope compared with the former serotype (16).
Clinical Features of FPLV 
and CPV in Their Original Hosts
Parvoviruses replicate most efficiently in rapidly dividing
cells. Replication is generally lytic, and tissue damage at these
sites can be observed (17). Infection with FPLV causes two
typical syndromes. When infection occurs in fetuses or very
young kittens, a distinct cerebellar ataxia is observed when
they become actively ambulatory (18,19). When older kittens
are infected, illness characterized by loss of appetite, pyrexia,
diarrhea, and leukopenia of both lymphocytes and neutrophils
appears (20). On the other hand, two typical syndromes
observed in CPV-infected dogs are acute myocarditis in young
puppies with a high mortality (21) and hemorrhagic enteritis in
older puppies (4,22). 
Mortality from FPLV infection is likely to depend on the
general condition of the animals before infection. Experimen-
tal infection of specific pathogen-free (SPF) or germfree cats
with FPLV generally leads to mild diseases (23,24). No or
slight intestinal lesions can be observed in infected germfree
cats (23), which suggests that the intestinal lesions are caused
by secondary bacterial, rather than primary viral, infection.
Host Range of FPLV- and CPV-Type Viruses
The host ranges of FPLV- and CPV-type viruses have been
extensively studied in vitro. In general, CPV-type viruses rep-
licate efficiently in feline and canine cell lines, while most
Table. Phylogenetically informative amino acid sequences in the VP2 gene
Virus 80 87 93 103 232 297 300 305 323 426 555 564 568
FPLV/MEV-1 Lys Met Lys Val Val Ser Ala Asp Asp Asn Val Asn Ala
MEV-2/BFPV Lys Met Lys Val Val Ser Val Asp Asp Asn Val Asn Ala
CPV-2 Arg Met Asn Ala Ile Ser Ala Asp Asn Asn Val Ser Gly
CPV-2a Arg Leu Asn Ala Ile Ser/Ala Gly Tyr Asn Asn Ile Ser Gly
CPV-2b Arg Leu Asn Ala Ile Ser/Ala Gly Tyr Asn Asp Val Ser Gly
CPV-2c(a) Arg Leu Asn Ala Ile Ala Asp Tyr Asn Asn Val Ser Gly
CPV-2c(b) Arg Leu Asn Ala Ile Ala Asp Tyr Asn Asp Val Ser Gly
FPLV = Feline panleukopenia virus; MEV = Mink enteritis virus; BFPV = blue fox parvovirus; CPV = Canine parvovirus.
Figure 2. Conserved nucleotide differences between the Feline panleu-
kopenia virus (FPLV)- and Canine parvovirus (CPV)-type viruses.
Nucleotide positions in the VP2 gene are numbered above the
sequences; BFPV = blue fox parvovirus.Emerging Infectious Diseases  •  Vol. 8, No. 4, April 2002 343
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FPLV and FPLV-like viruses can replicate efficiently only in
feline cells (11,25-27). Subsequent recombination mapping
and site-directed mutagenesis experiments have clearly shown
that the VP2 gene (including the differences of VP2 residues
93, 103, and 323; Table) is important in controlling canine host
range, although a part of the nonstructural NS gene of CPV
also participates in FPLV replication in canine cells (27,28).
Recently, Ikeda et al. (11) reported a unique FPLV isolate from
a domestic cat, which could replicate efficiently in a canine
cell line. Interestingly, this isolate was antigenically FPLV-
type but had a natural mutation of VP2 residue 323 Asp to
CPV-specific Asn, supporting previous site-directed mutagen-
esis studies. Moreover, FPLV-type virus actually has the
potential to acquire canine host range by natural mutation,
although phylogenetic analyses indicate that the isolate is
unlikely to be a direct ancestor of CPV-2 (11).
The in vivo host ranges of FPLV and CPV seem to be more
complicated. FPLV can replicate in feline tissues, such as
lymph nodes, thymus, spleen, or intestinal epithelial cells, and
high titers of virus are shed in feces. In dogs, however,  FPLV
replication is seen only in the thymus and bone marrow, not in
the gut or mesenteric lymph nodes (26), resulting in no virus
shedding in feces (29). In terms of viral evolution, the CPV
ancestor had only to gain the ability to infect the gut in order to
be shed and spread in the dog population (26). Indeed, Mochi-
zuki et al. (30) report the isolation of FPLV-type virus from
diarrheic feces of a clinically diseased dog. Although the rea-
son why the antigenically FPLV-type virus could gain canine
host range remains to be determined, the virus possibly had
some genetic mutation(s) that did not change its antigenic
properties yet rendered the virus able to infect canine gut cells. 
Until recently, the feline host range of CPV has been con-
troversial. Goto et al. report that CPV replicates in cats in a
pattern similar to FPLV (31); other studies find no detectable
CPV replication in any feline tissue (26,32). This discrepancy,
however,  is due to the antigenic differences of the examined
viruses. The virus (Kushiro strain) used in the first study (31)
was shown to be CPV-2a (27), whereas the other studies used
CPV-2 (26,32). Truyen et al. (33) directly compared the feline
host ranges among CPV-2, CPV-2a and CPV-2b and showed
efficient replication of both CPV-2a and CPV-2b in experi-
mentally infected cats. CPV-2a and CPV-2b isolates replicate
to high titers in lymphoid and intestinal tissues, while the
CPV-2 isolate used in this study did not replicate in experi-
mentally infected animals (33).
Feline Host Range of CPV in the Wild
In late 1980s, CPV was first recognized in cats in a natural
setting (30). Mochizuki et al. (30) examined eight feline iso-
lates collected during 1987 to 1991 in Japan and demonstrated
that three were antigenically and genetically identical to CPV-
2a viruses. The first isolation of CPV-2a-type virus from a cat
was in 1987 (30). All three CPV-2a-type viruses were isolated
from the feces of clinically healthy cats, while the isolates
from cats with typical feline panleukopenia were all conven-
tional FPLV-type. Subsequently, CPV-2a and CPV-2b viruses
were recognized in cats in the USA (2 of 20 isolates) and Ger-
many (3 of 36 isolates) (33). 
Recently, Ikeda et al. (11) examined 18 isolates from
unvaccinated cat populations and demonstrated that 15 of the
isolates could be classified as CPV-2a- or 2b-related viruses
(11). Since carnivore parvoviruses are likely to spread freely
and rapidly in the environment when few cats and dogs are
vaccinated against FPLV or CPV, CPV-2a/2b-type viruses
seem to have more advantages over conventional FPLV in cats
under natural conditions. It is therefore possible that CPV-2a/
2b-type viruses will replace FPLV-type viruses as the domi-
nant infectious agents in domestic cats even in developed
countries, where FPLV vaccines are commonly used.
Emergence of New Antigenic Types 
of CPV (CPV-2c) in Cats
Feline parvoviruses continue to evolve. CPV-2a and 2b
have been detected not only from domestic cats but also from
wild felids worldwide (11,34). Steinel et al. (34) report the
detection of CPV-2b-type viral DNA from one fecal sample of
a Namibian farm-raised cheetah and the tissue sections of four
captive cheetahs in the United States. CPV-2a-type sequence
was also found in the fecal sample of the Siberian tiger from a
German zoo (34). 
During 1996 to 1997, CPV-2a/2b-related viruses were iso-
lated from Asian small wildcats, leopard cats (Felis bengalen-
sis), in Vietnam and Taiwan (11,35). These viruses were
designated as leopard cat parvovirus (LCPV). Three of the six
isolates were demonstrated to be new antigenic types of CPV;
Figure 3. The apparent evolutionary processes of feline parvoviruses. PERSPECTIVES
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the other three isolates were essentially identical to CPV-2a or
2b. Subsequently, the new antigenic type viruses were shown
to have a natural mutation of VP2 in common (11) (residue
300 Gly to an Asp, Table), which results in remarkable
changes of their antigenic properties. The new antigenic type,
characterized by the loss of the VP2 epitopes recognized by
the reference MAbs A3B10, B6D5, and C1D1, is currently
designated as CPV-2c (Figure 1) (11). The reactivity against
MAb B4A2, which distinguishes CPV-2b from the other sero-
types, further classifies the CPV-2c-type isolates into two sero-
types, CPV-2c(a) and CPV-2c(b) (Figure 1). 
CPV-2c-type viruses have been isolated only from leopard
cats but not from domestic cats in the same area. Since the
phylogenetic analysis indicated that CPV-2a and CPV-2b-type
viruses were likely to evolve to CPV-2c(a) and CPV-2c(b)-
type viruses, respectively, the mutation at the residue 300 Gly
to Asp is probably ascribed to the adaptation of CPV-2a/2b-
type viruses to leopard cats. Similar to the emergence of CPV-
2a and CPV-2b, CPV-2c has lost neutralizing epitopes com-
pared with the former serotypes, CPV-2a and 2b. 
Virulence of CPV-2a and -2b in Cats
The pathogenicity of CPV-2a and 2b in cats remains debat-
able. Mochizuki et al. reported the isolation of CPV-2a from a
cat manifesting clinical signs of feline panleukopenia (36).
The detection of CPV-2a/2b-type DNA sequences from the
cheetahs with chronic diarrhea and enteritis or the tiger with
anorexia and diarrhea (34) strongly suggests CPV-2a’s and
CPV-2b’s pathogenic potential in large felids. In sharp con-
trast, recent studies using SPF cats experimentally infected
with CPV-2a or CPV-2b showed no or slight illness, such as
mild lymphopenia, in the infected animals (31,33,37,38).
Moreover, the fact that many CPV-2a- and CPV-2b-type
viruses were isolated from clinically healthy cats (11,30,35,39)
seems to indicate their relatively low pathogenicity.
At present, this discrepancy remains to be resolved. Note,
however, that the experimental infection of SPF cats with
FPLV generally leads to mild disease (23,24). In this regard,
the study reported by Goto et al. (31) is intriguing. These
researchers compared the clinical signs of five SPF and four
conventional cats experimentally infected with CPV-2a. The
infected five SPF cats showed neither clinical signs nor leuko-
penia through the observation period, while depression (four
cases), vomiting (two), diarrhea (one), and severe leukopenia
(four) were observed in the four conventional cats. One cat
died 4 days after infection (31). These data indicate that the ill-
ness from CPV-2a/2b infection highly depends on the general
condition of the cats before infection. 
Pathogenic Potential of CPV-2c
Since feline parvoviruses shed in the feces survive in the
environment for up to several months, a fecal-oral route is
considered to be the predominant means of their transmission.
Although CPV-2c-type viruses have been isolated only from
leopard cats (13,38), the new serotype viruses will likely
spread to domestic cat and dog populations. Nakamura et al.
(38) compared the virulence between FPLV, CPV-2a, and
CPV-2c in SPF cats. In this experiment, diverse pathogenicity
of the CPV-2a for individual cats was observed. One cat had
symptoms frequently associated with parvovirus infection,
including leukopenia and diarrhea; the other cats remained
asymptomatic. One cat showed no evidence of infection. In
contrast to the results obtained with CPV-2a-inoculated ani-
mals, all cats inoculated with CPV-2c developed diseases,
although the symptoms were relatively milder than those
observed in FPLV-inoculated cats. These data indicate that
CPV-2c and CPV-2a both have the potential to cause diseases
in cats, with some variations of symptoms. CPV-2c appears to
be more infectious in cats than CPV-2a and to induce a higher
frequency of disease than CPV-2a, although the numbers of
cats tested in the experiment were small. Since CPV-2a did not
produce any clinical symptoms in the infected SPF cats, yet
demonstrated strong virulence in the infected conventional
cats (31), it is also possible that CPV-2c infection results in
severe illness in conventional cats. 
The virulence of CPV-2c in dogs remains to be deter-
mined. The most probable hypothesis is that the new antigenic
viruses can infect dogs and cause some illness, as seen in the
emergence of CPV-2a and 2b in 1980s. However, the CPV-2c-
type viruses may also have lost their canine host range. The
latter hypothesis is based on the fact that CPV-2, which is
believed to have emerged from FPLV-related viruses, fails to
infect cats. The pathogenic potential of CPV-2c in dogs needs
to be addressed (Figure 3).
Persistent Infection of CPV in Cats
Animals that recover from feline parvovirus infection
retain high specific neutralization antibodies and show no
virus shedding. Although isolation of FPLV from apparently
healthy cats has been reported, feline parvoviruses are gener-
ally believed to be completely eliminated from recovered ani-
mals. 
As mentioned, CPV-type viruses have been isolated from
the fecal samples of apparently healthy cats (30). Moreover,
many CPV-type viruses were isolated from the peripheral
blood mononuclear cells (PBMC) of cats with high specific
neutralizing antibodies (11,35,39), suggesting that CPV could
persistently infect cats irrespective of the presence of the neu-
tralizing antibodies. Although precise mechanisms of the per-
sistent infection of CPV remain to be determined, PBMC
probably play a role as a reservoir for the viruses. If one
assumes that CPV actually infects cats persistently, examina-
tion will be needed to determine whether sporadic shedding of
the virus occurs in recovered cats. 
The Efficacy of Conventional FPLV 
Vaccines against CPV
The study of an attenuated live FPLV vaccine for CPV-2b
infection has shown that vaccinated SPF cats are protected
from challenge with CPV-2b at 2 weeks after vaccination (37).Emerging Infectious Diseases  •  Vol. 8, No. 4, April 2002 345
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A cross-neutralization study of the antibodies induced by an
inactivated FPLV vaccine demonstrated that the vaccinated
cats actually develop neutralizing antibodies against CPV-2a,
2b, and 2c as well as FPLV (40). These data indicate that com-
mercially available FPLV vaccines can be used for protection
against CPVs, at least in the short term. However, antibody
titers induced by a FPLV vaccine are significantly lower
against CPVs than FPLV (40). Indeed, CPV infection was
observed in the cheetahs vaccinated with a killed FPLV vac-
cine (34). We therefore suggest that FPLV vaccines are not
always sufficient to protect cats from CPV infection in the
long term. Steinel et al. (34) have proposed the need for inacti-
vated vaccines that use CPV-2a or 2b for cats. CPV-2a/2b-
based vaccines are expected to protect cats more efficiently
from CPV infection than conventional FPLV vaccines.
Recently, Nakamura et al. reported that cats experimentally
infected with CPV-2a develop high titers of neutralizing anti-
bodies against CPV-2a and 2b but show relatively low titers
against FPLV (40). Thus, like FPLV vaccines for CPV infec-
tion, CPV-2a/2b-based vaccines may be less efficient for
FPLV infection, which would be a major concern. Interest-
ingly, CPV-2c-infected cats showed similar neutralization anti-
body titers against FPLV, CPV-2a, and 2b as well as CPV-2c
(40). An inactivated CPV-2c-based vaccine for cats could be a
promising vaccine candidate against both CPV and FPLV
infection. 
Problems with the Current Parvovirus Nomenclature 
Finally, we point out problems with the current nomencla-
ture of carnivore paroviruses, including FPLV, MEV, and CPV.
As we mentioned, all carnivore parvovirus isolates are known
to be genetically closely related to each other; interspecies
transmissions readily occur among carnivores. On the other
hand, field isolates have been distinguished on the basis of the
host from which they are isolated. According to this system,
CPV-2a- and 2b-type isolates from cats should be designated
as FPLV types 2 and 3, even though they are essentially indis-
tinguishable from CPVs from dogs. To solve this problem, a
new nomenclature is needed. Naming any field carnivore iso-
late as feline parvovirus or carnivore parvovirus, irrespective
of their original hosts, and using the names such as FPLV and
CPV-2a to distinguish antigenic or genetic properties would be
more appropriate.
Conclusion
The evolutionary pattern of FPLV in cats differs from that
of CPV in dogs. Since FPLV is in evolutionary stasis in cats,
FPLV mainly evolves with random genetic drift (9). In con-
trast, CPV appears to evolve in dogs under certain positive
selection on the VP2 protein (9), which may be because of its
short history in dogs. How CPVs are evolving in cats remains
relatively obscure. Since CPV-2a and 2b are likely to act as
newly emerging parasites in cats, some cat-specific positive
selection(s), such as relative in vivo fitness and immune sur-
veillance, could operate as a driving force of CPV evolution.
The emergence of CPV-2c in leopard cats is a good example of
the evolution of CPV in new hosts. Similarly, since specific
antibodies against CPV have been detected in a wide range of
wild animals, such as large felids, wildcats, civets, otters, and
even bears, such interspecies transmissions probably result in
accelerated emergence of other new antigenic types of CPVs
because of the new host-specific positive selection. 
Elucidating how feline parvoviruses are evolving and how
newly emerging variants behave may help to prevent a possi-
ble outbreak of the new variant. Assuming that a new virulent
CPV variant emerges in cats in the future, what can we expect?
Fortunately, the newly emerging variant will not likely cause
rapid outbreaks in cats or dogs, since FPLV and CPV-2a/2b
have been actively circulating in carnivore populations. Com-
mercially available FPLV or CPV-2-based vaccines might also
protect animals from the new virus infection. However, if the
new virus gains wider host ranges, deadly outbreaks could be
observed, as when CPV-2 emerged in dogs. In any case, recent
isolates need to be investigated to anticipate and assess the risk
caused by newly emerging viruses. 
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